Endoskopia sp z o. o

Sopot, Pomeranian Voivodeship 81756

0 studies enrolling now · 14 studies all time

What they study most

Colitis, Ulcerative, Crohn's Disease, Diabetes Mellitus, Gastroparesis, Ulcerative Colitis

Studies at this site

• Determination of the Optimal Treatment Target in Ulcerative Colitis — Running, not enrolling
• VE202 in Patients With Mild-to-Moderate Ulcerative Colitis — Stopped early
• A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Running, not enrolling
• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed
• Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD) — Completed
• A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) — Completed
• Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD) — Status unconfirmed
• Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) — Stopped early
• An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis — Completed
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 — Stopped early
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 — Stopped early
• Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis — Stopped early
• Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305) — Stopped early